Hikma Pharmaceuticals Management
Management criteria checks 2/4
Hikma Pharmaceuticals' CEO is Riad Mishlawi, appointed in Sep 2023, has a tenure of 2.17 years. total yearly compensation is $3.51M, comprised of 28.5% salary and 71.5% bonuses, including company stock and options. directly owns 0.095% of the company’s shares, worth MX$79.61M. The average tenure of the management team and the board of directors is 2.2 years and 6 years respectively.
Key information
Riad Mishlawi
Chief executive officer
US$3.5m
Total compensation
| CEO salary percentage | 28.52% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.2yrs |
| Board average tenure | 6yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$371m |
| Mar 31 2025 | n/a | n/a | US$365m |
| Dec 31 2024 | US$4m | US$1m | US$359m |
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$285m |
| Mar 31 2024 | n/a | n/a | US$238m |
| Dec 31 2023 | US$2m | US$333k | US$190m |
Compensation vs Market: Riad's total compensation ($USD3.51M) is above average for companies of similar size in the MX market ($USD1.02M).
Compensation vs Earnings: Riad's compensation has increased by more than 20% in the past year.
CEO
Riad Mishlawi (61 yo)
Mr. Riad Ali Mishlawi has been Interim Head of Injectables Business at Hikma Pharmaceuticals PLC since November 2025 and serves as its Chief Executive Officer since September 01, 2023 as well as its Direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 18.3yrs | US$3.54m | 0.62% MX$ 515.1m | |
| Interim Head of Injectables Business | 2.2yrs | US$3.51m | 0.095% MX$ 79.6m | |
| Executive Vice Chairman & President of MENA | 20.2yrs | US$2.90m | 0.87% MX$ 725.3m | |
| Chief Financial Officer | 14.8yrs | no data | 0.22% MX$ 180.4m | |
| Chief Information Officer | no data | no data | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Executive Vice President of Corporate Development and M&A | 11.7yrs | no data | 0.24% MX$ 200.8m | |
| Chief People Officer | 2.2yrs | no data | no data | |
| Executive Vice President of Strategic Planning & Global Affairs | 7.8yrs | no data | no data | |
| Senior Vice President of Corporate Quality Compliance/Health & Safety | 1.8yrs | no data | no data | |
| Senior Vice President of Corporate Quality Compliance | no data | no data | no data |
Experienced Management: HIK N's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 18.3yrs | US$3.54m | 0.62% MX$ 515.1m | |
| Interim Head of Injectables Business | 2.2yrs | US$3.51m | 0.095% MX$ 79.6m | |
| Executive Vice Chairman & President of MENA | 20.2yrs | US$2.90m | 0.87% MX$ 725.3m | |
| Senior Independent Non-Executive Director | 3yrs | US$167.16k | 0.0013% MX$ 1.0m | |
| Independent Non-Executive Director | 9.1yrs | US$177.67k | 0.0032% MX$ 2.7m | |
| Non-Executive Director | 20.1yrs | US$116.96k | 0.53% MX$ 437.9m | |
| Independent Non-Executive Director | 5.5yrs | US$153.96k | 0.0020% MX$ 1.7m | |
| Independent Non-Executive Director | 3yrs | US$144.19k | 0.00045% MX$ 375.3k | |
| Independent Non-Executive Director | 6.4yrs | US$131.23k | 0.00050% MX$ 417.0k | |
| Chairman of West-ward Pharmaceuticals | no data | no data | no data | |
| Independent Non-Executive Director | 3.1yrs | US$128.41k | 0.0016% MX$ 1.3m |
Experienced Board: HIK N's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/21 14:52 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sidhartha Modi | Barclays |
| Simon Mather | Barclays |
| Emily Field | Barclays |